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tigecycline resistant A. baumannii strains in the hospital environ-
ment.
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Background: The gram-negative pleiomorphic A. baumannii is
ncreasingly recognized as a worrisome often, multidrug resistant
MDR), opportunistic and nosocomial agent. Its adhesiveness and
rought-resistance impairs eradication in the hospital environ-
ent. We analysed the impact of A. baumannii in our BWC.
Methods: Totally 48 thermally injured where co-colonized/co-
nfected with A. baumannii and 184 Isolates were microbiologically
VITEK2, BioMérieux) and genomically ﬁngerprinted by Rep-PCR
Diversilab, BioMérieux).
Results:Outof 48A. baumanniipositivepatients (22F/26M)with
ean age of 46, a Total Burned Surface Area of 22% (>50% 3th.
egree) 9 died, mainly from sepsis with P. aeruginosa. Nine were
ransferred from abroad. The length of stay was 37 days, while the
rst A. baumannii was detected after an average of 16 days. Co-
orbidity, mainly psychiatric disorders (10) or diabetes (6) was
resent in 30 patients, while all where co-colonized/infected with
ther bacteria, mainly with P. aeruginosa (21), MRSA (11), MSSA
11), MRSE (11), ESBL Enterobacteriaceae (8).
From 2006 to 2008 an outbreak occurred after transfer of a
rauma patient from Algeria (index case). From a pool of 3 genomi-
ally typedA. baumannii strains, detected at admission, two (T21 on
patients, T22, on 14 patients) became endemic and caused two
onsecutive epidemic peaks. Both were related to the EU clone I
nd MDR carbapenem resistant. Other genotypes (39 totally) were
ound but none caused an outbreak. All strains (N=184) where
ensitive to colistine except type T38, not related to the epidemic
solates, and isolated from 1 patient only.
The unit could only be freed of the epidemic strains after closure
f the unit and drastic hospital hygiene (HH) measures (isolation,
trict screening at admission) and continuous HH awareness
Conclusion: A. baumannii is difﬁcult to eradicate. In complex ill
atients, with co-morbidity and co-colonizations/infectionsA. bau-
anniiwas not associatedwith an increased attributablemortality.
creening at admission, especially after transfers from endemic
reas, and strict hospital hygiene measures are essential for the
anagement of A. baumannii. Colistine treatment did not cause
ajor adverse events. A. baumannii was only once isolated from
aemoculture. P. aeruginosa is still the most lethal.
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Background: Acinetobacter baumannii has wreaked havoc in
the ICUs of the clinical settings world widely. It has a formidable
capacity to develop antimicrobial resistance, survive dry and harsh
environment and resist desiccation as well as disinfection. The
infection caused by this pathogen has recently become a signiﬁ-
cant challenge and threats to the healthcare system. The aim of
this study was to evaluate the in-vitro susceptibility of clinical and
environmental isolates of A. baumannii to tigecycline and other
antibiotics, as well as to further estimate the in-vitro inﬂuence of
tigecycline on the growth kinetics and morphology of A. baumannii
isolates.
Methods: The antibiotic susceptibility was determined by disk
diffusion method. The Etest and broth dilution methods were both
used to determine the MICs. The growth kinetics of A. baumannii
was established and the effects of tigecycline at sub-MIC on cell
morphology were evaluated using TEM.
Results: Fifty seven percent and 75% of the clinical and envi-
ronmental isolates were MDR strains, respectively. Ninety ﬁve
percent of the clinical isolates were susceptible to tigecycline and
5% showed intermediate resistance with MIC ranging between
0.032 and 3 mg/L. Tigecycline susceptible and intermediate resis-
tance amongst the environmental isolates were 40% and 60%,
respectively, with MIC range of 0.5- 4 mg/L. The growth kinet-
ics demonstrated higher ability of the environmental isolates to
tolerate the antibiotic effects than the clinical isolates. Minor mor-
phological changes were showed by the environmental isolates
upon treatment with tigecycline compared with the clinical ones.
Conclusion: The relatively high resistance and tolerance proﬁle
among the environmental isolates suggest an insidious emergence
of tigecycline resistance amongstA. baumannii. Strict infection con-
trol procedures are imperative to prevent the dissemination of
